News - Page 7

CSL, which earlier this year shelved plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based flu shot and antivenom facility

Mark Cuban, the co-founder of online pharmacy Cost Plus Drugs, says his company would produce generic drugs in the U.S. if the FDA eliminated approval fees.

The Buckland Group launched Quvara Medical as the newest CDMO to debut this year after buying a former Becton Dickinson manufacturing site in the U.K. for an undisclosed price.

Excelsior Sciences, which spun out of investment firm Deerfield Management, has roped in $95 million to scale its chemical synthesis “smart bloccs” platform, invest in its internal pipeline and forge partnerships across

Tuesday, the European Council gathered behind new regulations that seek to diversify local biopharma supply chains, support collaborative drug procurement models and devise incentives to bolster drug production in the bloc.

The manufacturing center of excellence, proposed in a recent congressional bill, would boost innovation and train workers to bolster production talent throughout the industry.

Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s trade

Microsize, a U.S.-based CDMO that specializes in particle size reduction and control technologies, has linked with Switzerland’s Schedio Group to acquire a Lonza micronization facility for an undisclosed price.

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is

Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to